Yao Pharma

Executive Summary

Yao Pharma is a privately held, Shanghai-based biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapies for metabolic and cardiovascular diseases. Founded in 2010, the company has built a pipeline targeting high-prevalence chronic conditions including diabetes, obesity, hypertension, and dyslipidemia. With over 200 employees, Yao Pharma leverages deep expertise in Chinese clinical development to advance novel compounds through Phase 2 trials, aiming to address significant unmet medical needs in both domestic and global markets. The company's strategic focus on oral small molecules positions it to offer convenient, cost-effective alternatives to injectable biologics in these large therapeutic areas. As a Phase 2-stage entity, Yao Pharma's near-term value hinges on successful clinical data readouts and regulatory progress. The company is expected to report top-line results from its lead diabetes and obesity programs within the next 12-18 months, which could serve as pivotal inflection points. Additionally, partnering discussions for ex-China rights may accelerate, given the global demand for oral metabolic therapies. While the company remains private and lacks detailed pipeline disclosure, its position in China's rapidly growing biotech ecosystem and the prevalence of metabolic diseases underpin a moderate conviction in its potential.

Upcoming Catalysts (preview)

• Q3 2026Phase 2 data readout for lead diabetes candidate65% success
• Q1 2027Phase 2 top-line results for obesity program55% success
• H2 2026Potential licensing or partnership deal for ex-China rights40% success